2008 News Releases

Webcast Rodman & Renshaw Annual Global Investment Conference (Replay) 11/12/08 at 12:00 p.m. ET

Webcast Lazard Capital Markets Annual Life Sciences Conference (Replay) 11/19/08 at 1:00 p.m. ET

Webcast Piper Jaffray Healthcare Conference (Live) 12/02/08 at 1:00 p.m. ET

Receive E-mail Alerts

The news releases listed below were believed to be accurate in all material respects at the time of original issuance. Please note that we do not intend, and assume no obligation, to update, correct, or otherwise modify any of these press releases for events that occur subsequent to the original release date. We suggest you review the more recent press releases in order to receive the most current information made available by ARIAD.

Date Title   11/12/08 ARIAD To Present at the Lazard Capital Markets 5th Annual Healthcare Conference 11/06/08 ARIAD Reports Third Quarter 2008 Financial Results and Development Progress 11/05/08 ARIAD to Present at the Rodman & Renshaw 10th Annual Healthcare Conference 10/24/08 ARIAD Presents Preclinical Data on Its Kinase Inhibitor, AP24534, Demonstrating Mechanism-Based Activity in Solid Tumors 10/23/08 ARIAD to Webcast Conference Call on Third Quarter 2008 Financial Results 10/23/08 ARIAD Presents Preclinical Data on Deforolimus and Bicalutamide in Androgen-Independent Prostate Cancer 10/20/08 Ariad Announces Start of Phase 2 Clinical Study of Oral Deforolimus in Patients with Prostate Cancer 10/16/08 ARIAD to Present Data on Deforolimus and AP24534 at 20th Annual EORTC-NCI-AACR Symposium 10/07/08 Ariad Appoints Two New Members to Its Board of Directors 10/06/08 ARIAD Announces Favorable Ruling Permitting Immediate Appeal of District Court Findings on NF-(kappa)B Patent in Amgen Litigation 09/22/08 ARIAD Announces Court Rulings Regarding NF-(kappa)B Patent Lawsuit with Amgen 09/12/08 ARIAD Announces Merger with ARIAD Gene Therapeutics, Inc. 08/07/08 ARIAD Reports Second Quarter 2008 Financial Results 08/06/08 ARIAD Announces Start of Phase 2 Clinical Study of Oral Deforolimus in Patients with Advanced Endometrial Cancer 07/30/08 ARIAD Announces Start of Phase 2 Clinical Trial of Oral Deforolimus in Patients with Metastatic, HER2-Positive Breast Cancer 07/24/08 ARIAD to Webcast Conference Call on Second Quarter 2008 Financial Results 06/18/08 ARIAD to Webcast Presentation at the Jefferies 2nd Annual Healthcare Conference 06/05/08 ARIAD Announces Webcast of Its Annual Stockholders Meeting 05/28/08 ARIAD Appoints Former Bristol-Myers Squibb Executive to Lead Corporate Legal and Compliance Functions 05/22/08 ARIAD Initiates Phase 1 Clinical Trial of its Investigational Oral Multi-Targeted Kinase Inhibitor, AP24534, in Patients with Hematological Cancers 05/15/08 ARIAD to Present Clinical Data at ASCO on the Anti-Tumor and Safety Profile of Its Oral Investigational mTOR Inhibitor, Deforolimus 05/07/08 ARIAD Reports First Quarter 2008 Financial Results 05/02/08 ARIAD to Participate at the Leerink Swann Cancer Roundtable Conference 04/30/08 ARIAD to Webcast Conference Call on First Quarter 2008 Financial Results 04/15/08 ARIAD Presents Preclinical Deforolimus Data at American Association for Cancer Research Meeting in Support of Clinical Initiatives 04/08/08 Preclinical Data on ARIAD's Novel Investigational mTOR Inhibitor, Deforolimus, to Be Presented at the AACR Annual Meeting 03/13/08 ARIAD to Webcast Presentation at the Lehman Brothers 11th Annual Global Healthcare Conference 03/11/08 ARIAD to Webcast Presentation at the Cowen and Company 28th Annual Healthcare Conference 02/13/08 ARIAD Appoints Richard W. Pascoe as Chief Operating Officer and Expands Role of Timothy P. Clackson, Chief Scientific Officer 02/11/08 Ariad to Open NASDAQ Stock Market on February 13, 2008 02/07/08 ARIAD Reports Fourth Quarter and Year-End 2007 Financial Results 01/31/08 ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2007 Financial Results 01/08/08 ARIAD Announces 2008 Key Corporate Objectives and Plans for Development of Its Lead Oncology Product Candidates 01/02/08 ARIAD to Webcast Presentation at the 26th Annual JPMorgan Healthcare Conference